宫内发育迟缓合并肺动脉高压的诊治进展

Advances in Diagnosis and Treatment of Intrauterine Growth Restriction (IUGR) Complicated with Pulmonary Hypertension (PH)

摘要: 宫内发育迟缓(Intrauterine Growth Restriction, IUGR)指胎儿因病理因素无法达到其遗传潜力的生长水平，出生体重低于同胎龄第10百分位数或平均体重2个标准差(−2 SD)，是围产期死亡及远期神经发育障碍的重要危险因素。近年研究发现，IUGR新生儿中肺动脉高压(Pulmonary Hypertension, PH)的发病率显著升高(15%~30%)，其病理机制与慢性缺氧性肺血管重塑、胎盘源性炎症因子释放(如TNF-α、IL-6)，以及表观遗传调控异常(如eNOS基因甲基化失衡)等密切相关。一旦进展为新生儿持续性肺动脉高压(Persistent Pulmonary Hypertension of the Newborn, PPHN)，可因严重低氧血症诱发多器官功能障碍，死亡率可高达10%~20%，且幸存者常遗留认知障碍或运动功能障碍。目前研究聚焦于：1) 分子机制解析(如BMPR2信号通路异常、miRNA调控网络；2) 靶向治疗优化(如一氧化氮吸入联合磷酸二酯酶-5抑制剂)；3) 早期预警体系建立(基于胎盘多普勒血流参数联合血清生物标志物)。本文将对IUGR-PH的流行病学特征、病理生理机制、临床表现与临床管理、预防干预、未来展望等方面进行综述。

Abstract: Intrauterine Growth Restriction (IUGR) refers to a pathological condition in which the fetus fails to achieve its genetically determined growth potential, with birth weight below the 10th percentile for gestational age or 2 standard deviations (−2 SD) from the mean. It is a significant risk factor for perinatal mortality and long-term neurodevelopmental impairments. Recent studies have revealed a markedly increased incidence of Pulmonary Hypertension (PH) in IUGR neonates (15%~30%), with pathological mechanisms closely linked to chronic hypoxic pulmonary vascular remodeling, placenta-derived inflammatory factor release (e.g., TNF-α, IL-6), and aberrant epigenetic regulation (e.g., dysregulated eNOS gene methylation). Once progressing to Persistent Pulmonary Hypertension of the Newborn (PPHN), severe hypoxemia may trigger multi-organ dysfunction, with mortality rates as high as 10%~20%. Survivors often exhibit cognitive or motor deficits. Current research focuses on three key areas: 1) Elucidating molecular mechanisms (e.g., BMPR2 signaling pathway dysfunction, miRNA regulatory networks); 2) Optimizing targeted therapies (e.g., inhaled nitric oxide combined with phosphodiesterase-5 inhibitors); and 3) Establishing early warning systems (based on placental Doppler flow parameters and serum biomarkers). This review summarizes the epidemiological features, pathophysiological mechanisms, clinical manifestations, management strategies, preventive interventions, and future perspectives of IUGR-PH.